HIV vaccine safe for Phase II human trials Canadian university
claim no adverse effects from first tests Researchers from the
Schulich School of Medicine & Dentistry at Canada's University
of Western Ontario have issued a statement saying the first
phase of clinical trials of an HIV vaccine have produced “no
adverse effects observed including local reactions,
signs/symptoms and laboratory toxicities”. The Reg understands
the trial of the vaccine, dubbed'SAV001-H' involved only 40
patients, all of which were HIV-positive. Some of those
participating in the trial received a placebo. The researchers
say data from the trial is still being analysed, but say the
results they have been able to gather show “significant increase
in the HIV-1 antibody formations after SAV001-H administration
compared to the base line in some patients.” That result, along
with the lack of adverse effects, sees the researchers declare
“we are now prepared to take the next steps towards Phase II and
Phase III clinical trials” among a wide